Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Septerna
Biotech
Why biotechs can benefit from the 'rational' IPO environment
2024 saw a healthier IPO market than 2023, with activity triggered by M&A that occurred in the back end of '23, Morgan Stanley's Chirag Surti said.
Gabrielle Masson
Jan 24, 2025 10:30am
What can we learn from 2024’s biotech IPOs?
Dec 6, 2024 8:44am
Septerna goes public with upsized offering of $288M
Oct 25, 2024 10:29am
Septerna plans $158M IPO to fund readouts for GPCR pipeline
Oct 21, 2024 8:30am
GPCR firm Septerna files for IPO on strength of preclinical data
Oct 3, 2024 6:00am
Vertex gets in on GPCR game, paying Septerna $47M for program
Sep 12, 2023 9:05am
